← Leaderboards
Katherine Marie Eichinger
Duo Oncology Inc
$849,937
Attributed
$849,937
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $455K · FY2023–24$500K$375K$250K$125K$0
'23
'24
Funding mix
By agency
NIH$849,937 · 2
By mechanism
R41$849,937 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Solid Neoplasm”
- Kenneth Schultz · Trethera Corporation$9,160,719
- Timothy O'Connor · Rockefeller University$7,019,416
- Yicheng Wang · Immunova Therapeutics, Llc$4,000,000
- Javier Caravaca · University Of California, San Francisco$3,728,080
- Martin Pule · University College London$3,627,871
- Amy M Moskop · Medical College Of Wisconsin$3,357,500
Research focus
Solid NeoplasmOrganNanoparticlePenetrationTumor GrowthPancreatic Cancer ModelMalignant NeoplasmsNanomedicineOncologyPancreatic Cancer PatientsToxicologyTumorTissuesGemcitabineInnovationMalignant Neoplasm Of PancreasMaximum Tolerated DoseMouse ModelDoseCancer CellFormulationGrantExposure ToAntagonist
Grant awards (3)
Stroma-penetrating nanomedicine to improve treatment for pancreatic cancer$399,970
R41 · FY2024 · CA · contact PI
A novel dual-carrier ultrasmall nanomedicine for the treatment of stroma-rich pancreatic cancer$55,000
R41 · FY2024 · CA · contact PI
A novel dual-carrier ultrasmall nanomedicine for the treatment of stroma-rich pancreatic cancer$394,967
R41 · FY2023 · CA · contact PI